Fig. 1 · Structure

Documents & Downloads

MLN 0905

Cat. No. A12429 CAS 1228960-69-7

PLK1 inhibitor

MLN0905 is a potent, selective small-molecule PLK1 inhibitor. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lines.

In Stock

Publications for MLN 0905

1 publication citing this product

  1. Reyhane Piri, .et al. , Invest New Drugs, 2025, Apr;43(2):348-356 PMID: 40278989

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

MLN0905 preferentially engaged PLK1 in a live-cell NanoBRET assay using engineered HEK293 cells. Reported target-engagement IC50 values were 14 nM for PLK1, 6600 nM for PLK2 and 3000 nM for PLK3. These values describe intracellular tracer displacement rather than enzyme inhibition or cell viability. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PLK1 2 nM

Cellular Effect

Cell Line Activity Value Description Reference
HeLa EC50 29 μM Inhibition of PLK-1 T210D mutant in human HeLa cells assessed as inhibition of Cdc25c phosphorylation at Thr-96 after 2 hrs by immunostaining [PMID: 22070629]

MLN 0905 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of MLN 0905 from 2 published references. In vitro models include HCT116, A549, SW480 and HT-29 human cancer cell lines.

MLN 0905 In Vitro Studies

Prolonged MLN0905 exposure produced a model-dependent senescence-associated phenotype. After two weeks, HCT116, A549 and SW480 cells showed increased β-galactosidase staining with enlarged, flattened morphology; HT-29 cells did not show the same phenotype under their tested condition. These findings support context-dependent cellular responses rather than a uniform senescence outcome. [2]

Live-cell PLK isozyme target engagement

Cell-based study · Adherent HEK293 cells expressing N-terminal NanoLuc fusions of human PLK1, PLK2 or PLK3 [1]

MLN0905 displaced the intracellular tracer preferentially from PLK1. These are live-cell target-engagement IC50 values, not cell-free enzyme inhibition or cell-viability IC50 values. The model uses engineered fusion proteins in HEK293 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intracellular PLK1 target engagementIC50 14 nM[1]
Intracellular PLK2 target engagementIC50 6600 nM[1]
Intracellular PLK3 target engagementIC50 3000 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response testing; full MLN0905 dilution series is not specified in the retrieved main text.
Exposure duration
2 h equilibration at 37 °C before BRET measurement
Method
Live-cell NanoBRET competition assay with probe 11; extracellular NanoLuc inhibitor suppresses signal from membrane-compromised cells.
Vehicle
Inhibitors prepared as DMSO stocks and diluted in Opti-MEM; final DMSO percentage not specified.
Reported limits
Table 1 states an average of two technical replicates ±15%; this is not labeled SD or SEM. Independent biological replicate number and full MLN0905 titration range are not specified.
Methods and source locations

Compound reported in the paper: MLN0905; Compound label in the paper: MLN0905 in Table 1

Evidence applies to named MLN0905 in this engineered cell assay and does not validate an Adooq lot.

Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations

Intracellular PLK1 target engagement: NanoBRET tracer displacement; probe 11 at 0.2 µM — Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations

Intracellular PLK2 target engagement: NanoBRET tracer displacement; probe 11 at 1.0 µM — Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations

Intracellular PLK3 target engagement: NanoBRET tracer displacement; probe 11 at 1.0 µM — Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations

Model-dependent senescence-associated phenotype after prolonged treatment

Cell-based study · HCT116, A549, SW480 and HT-29 human cancer cell lines [2]

After two weeks of continuous MLN0905 treatment, HCT116, A549 and SW480 cells showed increased β-galactosidase-positive area and enlarged, flattened morphology relative to vehicle controls. HT-29 did not show the same staining or morphology. These endpoints support a senescence-associated phenotype; this experiment does not establish irreversible arrest after drug withdrawal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HCT116 β-galactosidase-positive area after 50 nM MLN0905Qualitative direction and reported p value Increased versus DMSO; p = 0.0159[2]
A549 β-galactosidase-positive area after 30 nM MLN0905Qualitative direction and reported p value Increased versus DMSO; p = 0.0033[2]
SW480 β-galactosidase-positive area after 20 nM MLN0905Qualitative direction and reported p value Increased versus DMSO; p = 0.032[2]
HT-29 senescence-associated staining and morphology after 20 nM MLN0905Qualitative negative result No β-galactosidase staining or flattened senescent-like morphology reported[2]

Literature-Reported Treatment Conditions

Treatment concentration
HCT116: 50 nM; A549: 30 nM; SW480 and HT-29: 20 nM
Exposure duration
Two weeks continuously, with one medium change; β-galactosidase staining for 24 h afterward.
Method
Cell treatment followed by β-galactosidase staining and morphology/image analysis.
Vehicle
DMSO control (Figure 5B); final DMSO concentration for this experiment not specified.
Reported limits
Replicate unit and number are not explicitly specified for Figure 5A–B; plotted points were not assumed to be independent experiments. Exact positive-area means were not read from the graph.
Methods and source locations

Compound reported in the paper: MLN0905; Compound label in the paper: MLN0905 in Figure 5A–B

Model- and exposure-specific cellular findings for MLN0905; no supplier-lot equivalence or universal cell-fate claim.

Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining

HCT116 β-galactosidase-positive area after 50 nM MLN0905: β-galactosidase staining and image analysis; Figure 5B reports mean ±SD and two-tailed Mann–Whitney test. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining

A549 β-galactosidase-positive area after 30 nM MLN0905: β-galactosidase staining and image analysis; Figure 5B reports mean ±SD and two-tailed Mann–Whitney test. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining

SW480 β-galactosidase-positive area after 20 nM MLN0905: β-galactosidase staining and image analysis; Figure 5B reports mean ±SD and two-tailed Mann–Whitney test. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining

HT-29 senescence-associated staining and morphology after 20 nM MLN0905: Qualitative Figure 5A microscopy and accompanying Results; HT-29 has no quantitative panel in Figure 5B. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining

MLN 0905 In Vivo Studies

In an HCT116 mouse xenograft efficacy experiment, oral MLN0905 at 23.3 mg/kg once daily for three consecutive days each week for three weeks produced tumor stasis over the 21-day study. Antitumor activity was significant versus vehicle (p < 0.001). The reported tumor-growth endpoint does not establish systemic safety or durable regression. [2]

Oral MLN0905 suppresses HCT116 xenograft growth

Animal study · HCT116 tumor-bearing mice; n = 10 animals/group in efficacy Methods [2]

Oral MLN0905 at 23.3 mg/kg on a three-days-per-week schedule for three weeks produced tumor stasis over the 21-day study compared with vehicle-treated controls. The supplementary caption reports significant antitumor activity (p < 0.001). This efficacy experiment does not establish systemic safety or durable regression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HCT116 xenograft tumor growth at day 21Tumor growth and reported p value Tumor stasis over 21 days; p < 0.001 versus vehicle[2]

Conditions shared by the study groups

Treatment course
3 weeks
Vehicle
Vehicle composition referred to previous work; not retrieved.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MLN0905 23.3 mg/kgVehicle-treated groupTumor stasis over 21 days; significant antitumor activity versus vehicle (p < 0.001).[2]
Vehicle controlComparator for MLN0905 treatmentTumor growth continued in the vehicle curve.[2]
MLN0905 23.3 mg/kg
Model: HCT116 xenograft-bearing mice; efficacy Methods report n = 10/group
Route: Oral
Frequency: Once daily for 3 consecutive days per week (3-on/4-off)
Reported limits: Exact strain/sex for the efficacy cohort, formulation composition and full statistical procedure are not restated in the retrieved efficacy methods; no tolerability endpoint is supplied with Figure S8A.
Vehicle control
Model: HCT116 xenograft-bearing mice; efficacy Methods report n = 10/group
Reported limits: Exact strain/sex for the efficacy cohort, formulation composition and full statistical procedure are not restated in the retrieved efficacy methods; no tolerability endpoint is supplied with Figure S8A.
Methods and source locations

Compound reported in the paper: MLN0905; Compound label in the paper: MLN0905, Figure S8A

Preclinical HCT116 xenograft efficacy under the reported schedule; no Adooq lot validation, clinical efficacy or systemic safety inference.

Figure S8A and supplementary caption; Methods: In vivo efficacy studies; Results: final paragraph of Plk1 inhibition in vivo leads to mitotic arrest, DNA damage, senescence, and tumor stasis

HCT116 xenograft tumor growth at day 21: Tumor size measured with vernier calipers; Figure S8A plots average tumor volume ±SEM. Statistical procedure is referred to prior publications, not restated here. — Figure S8A and supplementary caption; Methods: In vivo efficacy studies; Results: final paragraph of Plk1 inhibition in vivo leads to mitotic arrest, DNA damage, senescence, and tumor stasis

MLN0905 23.3 mg/kg · Figure S8A and supplementary caption; Methods: In vivo efficacy studies; Results: final paragraph of Plk1 inhibition in vivo leads to mitotic arrest, DNA damage, senescence, and tumor stasis

Vehicle control · Figure S8A and supplementary caption; Methods: In vivo efficacy studies; Results: final paragraph of Plk1 inhibition in vivo leads to mitotic arrest, DNA damage, senescence, and tumor stasis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1228960-69-7
Applications PLK1 inhibitor
Formula C24H25F3N6S
Molecular Weight 486.56
SMILES
CC1=C(C=C(C=N1)CCCN(C)C)NC2=NC=C3CC(=S)NC4=C(C3=N2)C=CC(=C4)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (191.13 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MLN 0905 Research References

  1. [1] Xuan Yang, Jeffery L. Smith, Michael T. Beck, et al. Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells Molecules (2023). PMID: 37049713 DOI: 10.3390/molecules28072950 Source material
  2. [2] Denise L. Driscoll, Arijit Chakravarty, Doug Bowman, et al. Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines PLOS ONE (2014). PMID: 25365521 DOI: 10.1371/journal.pone.0111060 Source material

Publications

1 publication citing this product

  1. Reyhane Piri, .et al. , Invest New Drugs, 2025, Apr;43(2):348-356 PMID: 40278989

Added to your cart

View Cart Checkout
Loading...